



Alex Ocampo, Sanne Roels, Kelly Van Lanker, Tim Morris, Jesper Madsen

PURPOSE

- Apply advances in causal inference methodology to address industry applications in RCT's, while considering the framework of ICH, e.g. E9(R1), and guidelines from health authorities;
- Promote a causal perspective on the data generating mechanisms in RCTs to facilitate selection of the appropriate methodology that best addresses the scientific question of interest;
- Promote careful selection of estimators for the estimand of interest;
- Promote evaluation of causal inference assumptions via sensitivity analyses;
- Foster discussion on the practical implications of non-collapsibility, accounting for baseline covariate (including marginal versus conditional estimands), selection bias, etc.

CORE LEADERSHIP TEAM



Alex Ocampo

Novartis, Switzerland Interests: Mediation Analysis, Causal Graphs, Survival Analysis, Semiparametric Theory



Sanne Roels

Johnson & Johnson, Belgium Interests: Covariate adjustment, Surrogate markers, Causal inference



Kelly Van Lanker

Ghent University, Belgium *Interests: Covariate Adjustment, Causal Inference, Treatment Effect Transportability*



Tim Morris

University College London, UK Interests: Missing Data & Causal Inference, Conditional vs. Marginal Estimands

Jesper Madsen



Novo Nordisk, Denmark Interests: Mediation, Dynamic Path Analysis

OBJECTIVES

Cre for thin
Pro scie ser
Dev imp cau thir
Put ma infe
app Bui cau

Our new SIG welcomes those from industry, public health, academia and regulators and includes the following members:

Our SIG was formed this year and is thus actively recruiting more members.

Please refer to QR code to join!











eate a community of best practices the application of causal inference nking and application;

pose invited sessions to the ientific conferences and invited minars throughout the year;

evelopment a white paper on the plementation and application of usal inference methodology and nking in the analysis of RCT data;

blish peer-reviewed scientific nuscripts demonstrating causal erence methodologies and plications in RCTs

ild consensus on best practices for usal inference in RCTs

Develop tools and strategies for communicating causal concepts to non-statistical colleagues

SIG MEMBERS

• Yannis Jemiai, Cytel, USA Hongseok Kim, CSL Behring • Baldur Magnusson, UCB, CH • Hege Michiels, Argenx, Belgium Simon Newsome, Novartis, CH Silvia Noirjean, GSK, Spain • Jim Rogers, Metrum Research, USA • Kasper Rufibach, Merck, CH • Tina Sotto, J&J, Belgium

BECOMING A MEMBER

The working group is open for all interested who are working in clinical trials and commit to actively contribute to this SIG: i.e. who are willing to contribute to prepare materials, sharing experience for exemplary use, etc. Membership is limited to at most 2 people per institution.

Applications including a brief biography and short description on motivation will be considered. Please send applications as per to Kelly Van Lanker (Kelly.VanLancker@UGent.be) and Sanne Roels (sroels4@ITS.JNJ.com)

ACTIVITIES

Upcoming Webinar Joint PSI/EFSPI Casual Inference SIG Webinar: **Opportunities in applying a causal inference** framework during the analysis of an RCT

- Location: Online via Zoom
- Members

Monthly Group Meetings

- various topics in causal inference.
- Table 1.

Conference and Workshop Ambitions

EUROCIM 2025 - Ghent, Belgium □ ISCB 2025 - Basel, Switzerland

□ PSI 2025



Scientific question

Does undergoing colonoscopy have a causal effect on risk of death?

Randomized to Colonoscopy (Z)



GSK





□ Tuesday, November 19th. 15:00-16:30 CET The event is free to both Members of PSI and Non-

The SIG organizes monthly group meetings to discuss

The goal of these meetings is to build an inclusive learning environment where we can share knowledge to bring back to our individual institutions.

To choose the topics for the group meetings, we first conducted a survey, and members were asked to vote on the topics of interest. The poll results are presented in

A CLINICAL TRIAL EXAMPLE

Underwent Death Colonoscopy U

Topic

Mediation analys development

Understanding of mechanism (DAG,

Analyses conditio events, estimatio hypothetical and estimand and sen

Baseline covariat marginal & condi

Extrapolation to c questions around extrapolation / tr

Sensitivity analyse assumptions

Use of external d e.g., external con design

Alternative infere causal inference

Approaches for m linking to implem

Estimating hetero treatment effects

Table 1. Voting results on potential causal topics for SIG

Would the intention-to-treat analysis identify a causal effect? i.e., E[Y | Z=1] vs. E[Y | Z=0]Would the per-protocol analysis identify a causal effect? i.e., E[Y | Z = A = 1] vs. E[Y | Z = A = 0]Would either of these analysis answer the scientific question?









Scan QR code for our website

	Votes
is and its role in drug	10
data generating , SWIGs)	6
ned on post-baseline n strategies for principal stratum sitivity analyses	6
e adjustment - tional estimands	5
other populations and the degree of cansportability	5
ses for identification	2
ata to clinical trials: trol arms, hybrid	2
ential approaches to	1
nissing (observed) data, entation in estimation	1
ogeneous (conditional)	1